Studies show that up to
~1 IN 6
patients with LVH4,10
and
~1 IN 7
patients with HFpEF4,6
are likely to have ATTR-CM
KEY RED FLAGS OF ATTR-CM:1,7–9


GO BEYOND HEART FAILURE AND
CONSIDER THE UNDERLYING CAUSE






Alnylam Pharmaceuticals is responsible for the funding and content of this website. The site is intended for Healthcare Professionals in Europe (including UK), Canada and Japan. For disease awareness purposes only.
Studies show that up to
patients with LVH4,10
and
patients with HFpEF4,6
are likely to have ATTR-CM







